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The success of γδ T cell-based immunotherapy, where the cytotoxic activity of circulating
γδ T lymphocytes is activated by nitrogen-containing bisphosphonates (n-BP), or possibly
by bispecific antibodies or the combination of both, requires a profound knowledge of
patients’ γδ T cells. A possible influence of radio- or chemotherapy on γδ T cells as well
as their reported exhaustion after repetitive treatment with n-BP or their lack of response
to various cancers can be easily determined by the monitoring assays described in this
perspective article. Monitoring the absolute cell numbers of circulating γδ T cell subpop-
ulations in small volumes of whole blood from cancer patients and determining γδ T cell
cytotoxicity using the Real-Time Cell Analyzer can give a more comprehensive assessment
of a personalized tumor treatment. Possible future directions such as the combined usage
of n-BP or phosphorylated antigens together with bispecific antibodies that selectively
target γδ T cells to tumor-associated antigens, will be discussed. Such strategies induce
expansion and enhance γδT cell cytotoxicity and might possibly avoid their exhaustion and
overcome the immunosuppressive tumor microenvironment.
Keywords: monitoring, human, γδT cells, pancreatic ductal adenocarcinoma, bispecific antibodies, phosphorylated
antigens, aminobisphosphonate
INTRODUCTION
Human γδ T cells (γδTc) represent a small subset (1–10%) of
CD3+ T lymphocytes with several unconventional features. Sim-
ilar to antigen presenting cells (APC), γδTc can phagocytose and
present soluble antigens to CD3+ αβ T cells (1, 2). Additionally,
γδTc can induce the maturation of dendritic cells (DCs), and kill
various tumor cells in a HLA-independent manner (3, 4). Thus,
there is a substantial interest in γδTc in the context of T cell-
based immunotherapeutic strategies (5, 6). Several pilot studies
have described a partial success of γδ T cell-based immunother-
apy in different types of cancer after the application of amino-
bisphosphonates (n-BP) or phosphorylated antigens (PAg) plus
IL-2 in vivo or after repetitive transfer of in vitro expanded Vδ2-
expressing γδTc (7–10). Although γδ T cell-based immunotherapy
has delivered promising results, sustained stimulation of Vδ2 γδTc
by n-BP or PAg often leads to Vδ2 T cell exhaustion (8, 11, 12).
Additionally, a low number of functionally unresponsive γδTc has
been described in patients with chronic lymphocytic leukemia or
multiple myeloma (13–15). Novel bispecific antibodies (with con-
comitant specificity for epitopes on both γδTc and tumor cells)
provide a tool to enhance cytotoxic activity of γδTc against cancer
cells by selectively targeting γδTc to antigens expressed by tumor
Abbreviations: BrHPP, bromohydrin-pyrophosphate; γδTc, γδ T cells; mAb, mon-
oclonal antibody; n-BP, nitrogen-containing bisphosphonate; PAg, phosphorylated
antigens; PDAC, pancreatic ductal adenocarcinoma; RTCA, real-time cell analyzer;
TCR, T cell-antigen receptor.
cells (16). Additionally, independent of previous immunothera-
peutic strategies and prior to the application of a γδ T cell-based
immunotherapy, it is mandatory to analyze the number and func-
tional capacity of patients’ γδTc in a simple manner. This article
demonstrates that the analysis of absolute cell numbers of cir-
culating γδTc from patients as well as the determination of the
cytotoxic capacity against tumor cells of interest can give a better
assessment of subsequent personalized tumor treatment.
MONITORING OF ABSOLUTE CELL NUMBERS
The monitoring system that uses the BD Multitest 6-color
TBNK (M6T) Reagent with BD Trucount™ Beads (www.bd.com/
resource.aspx?IDX=17743, BD Biosciences, San Jose, CA, US)
allows determination of absolute cell numbers of αβ T and B lym-
phocytes and NK cells as well as CD4+ and CD8+ T cell subsets
(17, 18). Since γδ T lymphocytes and their subpopulations are not
detected by the M6T, we adapted γδTc staining from the BD Tru-
count™ Tube technical data sheet (version 8/2010) as follows: 50 µl
whole blood from cancer patients were stained with anti-CD45-
PE/Cy7 (clone HI30), CD3-PE (clone SK7) pan-TCRγδ-APC
(clone 11F2, customized) (all from BD Biosciences, Heidelberg,
Germany), and Vδ2-PerCP (clone B6, Biolegend, Fell, Germany)
mAbs and occasionally with Vδ1-FITC mAb (clone TS8.2, Thermo
Fisher Scientific, Germany) in BD Trucount™ Tubes as described
(16). After staining, red blood cells were lysed with 200 µl BD
Lysing buffer and analyzed using the FACS Canto flow cytome-
ter and FACS Diva software (both from BD Biosciences). For two
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FIGURE 1 | Determination of the absolute cell number of circulating
γδT cells and their subsets in blood of PDAC patients. Fifty microliters
whole blood samples from PDAC patients were stained with the indicated
mAb in BD Trucount™ Tubes. These mAbs were previously titrated and a
final concentration of 2–5 µg/ml was used. The mAb cocktail can be
prepared in advance in bulk. The BD Trucount™ tubes contain lyophilized
pellets that dissolve after adding liquid, thereby releasing a known
number of fluorescent beads. Two hundred microliters of BD Lysing buffer
was added to lyse red blood cells. To distinguish lymphocytes and beads
from granulocytes and monocytes, an appropriate gate was set on CD45+
cells or beads using side scatter and CD45 or CD3 expression,
respectively (upper panel). The ratio of the event number in the bead gate
was compared to the total number of beads originally in the tube. The
absolute cell number (Abs. Counts) of CD3+ (CD3), CD3+ TCRγδ+ (γδ),
TCRγδ+ TCRnon-Vδ2+ (non-Vδ2), and TCRγδ+ TCRVδ2+ (Vδ2) within CD45+
lymphocytes was calculated as follows: (cells/microliter of whole
blood)= [(events of cells of interest)/(ratio of acquired bead events to total
beads in pellet)]/50 µl. Two representative determinations (PDAC-Donor
7 and 2) of 21 are shown, as are the percentages of the different cell
populations.
representative donors, the absolute numbers of total γδTc as well
as Vδ2 and non-Vδ2 subsets are shown (Figure 1). Moreover,
cells can be stained with anti-Vδ1 mAb labeled with an additional
fluorochrome (data not shown).
Certainly, other bead-based detection systems could be used
alternatively to determine absolute cell numbers. Importantly,
however, these strategies must allow this determination from a
small volume of patient’s blood.
In addition, a possible influence of radio- or chemotherapy
on circulating immune cell numbers can be easily determined by
this monitoring system. For instance, our own data reveal that
the absolute number of Vδ2 γδTc in a cohort of 10 breast cancer
patients receiving chemotherapy did not differ from age-matched
breast cancer patients without treatment (Adam-Klages et al.,
unpublished data). Moreover, in a cohort of 41 patients with pan-
creatic ductal adenocarcinoma (PDAC, stage pT3–4, pN0–1, L0–1
andV0–1),we recently observed that the decrease in absolute num-
bers of Vδ2 γδTc did not correlate with cancer stage/progression,
but rather with patient age (16).
While determination of the absolute γδ T cell numbers and
that of their subsets provides no information about their cyto-
toxic capacity, this can be addressed in an additional functional
assay.
DETERMINATION OF CYTOTOXIC CAPACITY
We recently examined the functional capacity of γδTc from
patients with PDAC (16). PDAC is a highly aggressive gas-
trointestinal malignancy characterized by the presence of
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desmoplastic stromal microenvironment where conventional
treatment approaches including surgery, chemotherapy, and/or
radiation are often not effective (19). The observed decrease in
absolute Vδ2 T cell numbers in untreated patients with advanced
PDAC is attributable to age, not disease status, as similar numbers
were found in age-matched healthy controls (16). In an attempt to
avoid Vδ2 T cell exhaustion through repetitive n-BP stimulation
and overcome the immunosuppressive activity of PDAC stromal
cells on cytotoxic γδ T cells, novel bispecific antibodies such as
[Her2xCD3] and [(Her2)2xVγ9] were designed. [(Her2)2xVγ9] is
specific for Vγ9 on γδTc (associated with Vδ2) and for human epi-
dermal growth factor receptor HER2/neu overexpressed on PDAC,
breast, and prostate cancer cells. The [(Her2)2xVγ9] tribody
design allows monovalent binding to γδTc and bivalent HER2-
targeting, which enhances avidity to the tumor cell and thereby
increases cytolytic activity. Both bispecific antibodies selectively
target γδTc to tumor antigens, thereby enhancing the cytotoxic
activity of γδTc in vitro as well as in vivo in a PDAC grafted
SCID-Beige mouse model (16).
In previous studies, we usually examined the functional capac-
ity of γδ T cell lines or freshly isolated γδ Tc. Aiming to simplify
handling of cells from patients with a low γδ T cell number in
the following experiments, we investigated the functional capacity
of cytotoxic γδTc within PBMC. We observed that the functional
cytotoxic activity of circulating γδTc from patients can be deter-
mined in as few as of 1–2× 106 PBMC, readily obtainable from
2 to 4 ml of patients’ blood. We analyzed blood from 21 patients
with PDAC after obtaining their informed consent and relevant
institutional review board approvals (code number: D401/14). As
a read out system for cytotoxic activity of γδTc within freshly
isolated PBMC, the real-time cell analyzer (RTCA) single-plate
system (ACEA, San Diego, CA, USA) was used. RTCA measures
the impedance of adherent tumor cell monolayers, but not of sus-
pended cells such PBMCs with electronic sensors. The measure-
ment of impedance in arbitrary cell index units reflects changes
in cellular parameters of tumor cells, which allows monitoring
of cellular events in real time without the incorporation of labels
over time periods of several days. The loss of impedance correlates
with the γδ T cell-mediated lysis of tumor cells (16). A further
advantage of measuring impedance over an extended time is that
it enables us to observe whether tumor cells can regenerate when
lysis is incomplete.
To ensure adherence of tumor cells, PDAC cells were cultured
for 24–27 h in RTCA plates before the addition of γδTc alone with
or without additional substances. Thereafter, PDAC cells were still
cultured alone or together with PDAC patient-derived PBMC in (i)
medium, (ii) PAg such as bromohydrin-pyrophosphate (BrHPP),
or (iii) [(Her2)2xVγ9]. During the extended time course, we
observed that γδTc within PBMC required almost 24–36 h after
initial stimulation to exert their cytotoxic capacity (Figure 2A, red
arrow with a star). Moreover, we observed that [(Her2)2xVγ9]
triggered tumor cell lysis more efficiently than PAg in 30% of
PDAC patient samples (Figure 2A, responder), while neither sub-
stance was effective in 70% of patient samples (Figure 2A, non-
responder). The unexpected cytotoxicity against PDAC cells in
the absence of a stimulus (medium, orange line) is likely due to
the reactivity of NK cells in the presence of IL-2 (Figure 2A),
because additional experiments with untouched, freshly isolated
γδTc demonstrated that cytotoxic activity of γδTc is not induced
by IL-2 alone (16).
Regarding the absolute Vδ2 T cell numbers presented in
Figure 2B (table), we correlated the unresponsiveness of the
majority of the tested patient samples [negative [(Her2)2xVγ9]
reactivity] with their low initial Vδ2 T cell number. PBMC from
patients with more than 30 Vδ2+ γδTc/µl blood were responsive
(responder in Figure 2A and “positive” in Figure 2B), whereas
in samples with <30 Vδ2+ γδTc/µl blood, no induction of cyto-
toxic activity to PAg or [(Her2)2xVγ9] stimulation was observed
(non-responder in Figure 2A and “negative” in Figure 2B).
The weak capacity of bispecific antibodies to induce γδ T
cell proliferation could explain the observed unresponsiveness to
[(Her2)2xVγ9]. Therefore, PBMC from the same patients were
stimulated with the PAg BrHPP or, as presented in Figure 2C,
with n-BP zoledronic acid for 7–14 days. Although the respon-
der cells expanded to 80% γδTc in culture, while non-responders
comprised only 7% after n-BP stimulation, this small population
of non-responders exhibited nearly the same degree of cytotoxic-
ity as responders after re-stimulation with [(Her2)2xVγ9], despite
the lower effector/target ratio (Figure 2C).
Taken together, our results demonstrate that prior analysis of
absolute circulating cell numbers of immune cell subsets as well
as determination of their cytotoxic capacity against tumor cells of
interest may provide a better assessment of whether a particular
personalized tumor treatment will be effective.
WHAT CAN WE LEARN FROM THIS MONITORING SYSTEM?
γδ T cell monitoring can provide an estimate for a potential treat-
ment of cancer patients. Although knowledge of the functional
capacity of γδTc within PBMC does not provide information
about their migration and infiltration into the tumor, characteri-
zation of these circulating γδTc is useful since they are activated by
intravenous n-BP or PAg administration (8, 10). In clinical trials
where γδTc were repetitively activated with n-BP or PAg together
with low-dose IL-2, effects on tumor growth were observed; how-
ever, this was associated with exhaustion, anergy, or depletion of
γδTc due to repetitive stimulation (8, 11, 12). In light of these
observations, it is necessary to optimize cytotoxic activity, which
can be achieved with bispecific antibodies such as the tribody
[(Her2)2xVγ9]. Adoptive transfer of γδTc with [(Her2)2xVγ9]
and IL-2 significantly reduced growth of pancreatic tumors grafted
into SCID-Beige mice in comparison to adoptively transferred
γδTc together with n-BP and IL-2 (16).
Vδ2 γδTc used for adoptive transfer are cells within PBMC
that are initially activated with n-BP or PAg plus IL-2 (7, 20).
Such initial activation with n-BP or PAg plus IL-2 causes selec-
tive Vδ2 T cell-expansion, while [(Her2)2xVγ9] does not induce
strong proliferation of γδTc (unpublished data). Independently of
the proliferative response of γδ Tc, the cytotoxic activity of PAg
or n-BP expanded Vδ2 T cell lines can be significantly enhanced
after re-stimulation with [(Her2)2xVγ9]. Moreover, the addition
of [(Her2)2xVγ9] did not induce cell death of Vδ2 T cells, in con-
trast to restimulation of Vδ2 T cell lines with PAg (unpublished
data). Thus, [(Her2)2xVγ9] provides a tool to further enhance
cytotoxic activity of adoptively transferred γδTc, whereas PAg or
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FIGURE 2 | Correlation between absolute cell number and functional capacity of Vδ2T cells.
(Continued)


























































Oberg et al. Monitoring to optimize γδ T cell-based immunotherapy
FIGURE 2 | Continued
(A) Flow cytometric analysis of CD3+ Vδ2+ γδTc within PBMC, and RTCA of
PBMC from two representative donors (Donors 7 and 2) of 21; (B) list of the
relative and absolute numbers (abs.) of CD3, γδ, Vδ2, and non-Vδ2 T cells in
whole blood from 11 representative PDAC patients out of 21 as well as
reactivity to the tribody; (C) flow cytometric analysis of selective expansion
of CD3+ Vδ2+ γδTc after PAg-activation within PBMC for 8 days, and RTCA
with these short-term expanded γδTc from Donors 7 and 2. Two
representative donors of 21 are shown. (A,C) For RTCA, 5×103 PDAC cells
(PancTu-I) were cultured in 10% FCS RPMI medium for 24–27 h on an
E-plate covered at the bottom with electronic sensors that measure the
impedance of the cells expressed as an arbitrary unit called cell index (CI).
The CI was analyzed every 5 min to determine adherence and thus cell
growth. Since the initial adherence in different wells can differ slightly, the CI
was normalized to 1 shortly before the time of addition of suspended
cells± substances (vertical black line). After 24–27 h, PDAC cells were
treated again with medium [green line (0)] or with PBMC (A) or short-term
expanded γδTc (C) together with medium [orange line (i)], 300 nM PAg
BrHPP [dark blue line (ii)], or 1 µg/ml [(Her2)2xVγ9)] [red line (iii)] at the
indicated E:T ratio over the indicated time. As a positive control for maximal
lysis, PDAC cells were treated with Triton X-100 [TX-100, black line (iv)]. The
addition of substances, PBMC or expanded γδTc is indicated by the blue
arrow. CI was then measured every minute for analysis of precise
cytotoxicity time point for >15 to 55 h as indicated. The loss of tumor cell
impedance and thus a decrease of the Normalized CI correlates with γδ T
cell-mediated lysis of PDAC cells. The red arrow with the * points out the
initiation of cytotoxicity. The average of triplicates and standard deviation
were calculated; one representative experiment is shown.
n-BP failed because they induce cell death in almost half of the
activated cells (unpublished data).
The observation that the majority of elderly people has a low
frequency of γδTc hampers the expansion of autologous γδTc
required for adoptive transfer. Considering these challenges, one
might suggest adoptively transferring allogeneic or haploidentical
γδTc from (younger) healthy donors or activating γδTc within
PBMC in vivo with bispecific antibodies (21–23). To investigate
the effect of bispecific antibodies on unstimulated γδTc, we mon-
itored whether [(Her2)2xVγ9] can induce cytotoxic activity in
γδTc within PBMC. As described above, no or weak responses
to [(Her2)2xVγ9] were obtained with PBMC from PDAC donors
with a lower frequency of Vδ2 γδTc (non-responder), whereas
PBMC with a higher Vδ2 γδ T cell frequency responded to
[(Her2)2xVγ9] resulting in enhanced cytotoxicity (responder)
(Figure 2A). Interestingly, n-BP- or PAg-mediated enrichment of
non-responder γδTc within PBMC for 7–14 days led to enhanced
cytotoxic activity after restimulating the cells with [(Her2)2xVγ9]
(Figure 2C).
The validity of this monitoring system to determine γδ T cell-
reactivity within PBMC needs to be confirmed in patients under-
going γδ T cell-targeting therapy. Based on our experience, one
might suggest initially administration of n-BP together with IL-2
in cancer patients to induce proliferation of Vδ2 γδTc followed
by treatment with bispecific antibodies engaging γδTc plus IL-2
in order to avoid the Vδ2 T cell exhaustion observed in patients
mediated by repetitive application of n-BP plus IL-2.
WHAT ARE THE BENEFITS OF COMBINING γδ T CELL-BASED
IMMUNOTHERAPY WITH BISPECIFIC ANTIBODIES?
Therapeutic antibodies such as rituximab (anti-CD20 mAb) and
trastuzumab or pertuzumab (both anti-HER2 mAb) as well as
different combined therapies have clearly improved the treat-
ment outcome of patients with B-cell lymphoma or breast can-
cer, respectively (24, 25). Furthermore, combining these thera-
peutic antibodies with γδ T cell-based immunotherapy seems
very promising. Rituximab enhanced cytotoxic activity of ex vivo
expanded CD16+ (FcRγIII) γδTc against CD20+ chronic lympho-
cytic leukemia, while Trastuzumab increased γδ T cell cytotoxicity
against HER2+ breast cancer cells (26).
The success of such therapeutic antibodies has inspired anti-
body engineers to improve the antibody efficacy. One promising
approach to enhance cytotoxicity and selectively target T cells to
tumor-associated antigens is based on the usage of single-chain
bispecific antibody constructs. One such construct is Blinatu-
momab with specificity for CD19 on lymphoma or leukemia and
CD3 on T cells, which has proved efficient for the treatment of
patients with hematological malignancies (27). The short half-life
of only a few hours in serum requires continuous intravenous infu-
sion of Blinatumomab,which induces an almost complete molecu-
lar response and prolonged leukemia-free survival in patients with
minimal residual B-lineage acute lymphoblastic leukemia (28).
The favorable characteristics of bispecific antibodies such as high
specificity, high cytotoxic potential, and low immunogenicity, led
us to design a bispecific antibody targeted to Vγ9 instead of CD3
and to HER2 expressed on several PDAC as well as on breast and
prostate cancer, which could be easily replaced by another tumor
target antigen of interest.
Of course, the question arises as to what differentiates bispecific
antibodies with specificity for γδTc and those with specificity for
CD3 T cells. For instance, a target group could be patients with
advanced hematological malignancies (e.g., AML) who require
allogeneic stem cell transplantation. A major advantage of γδ
T cell-based immunotherapy is the HLA-independent killing of
tumor cells, thereby reducing the risk of graft-versus-host dis-
ease often caused by alloreactive CD3+ αβ T cells (21, 22, 29, 30).
A successful anti-tumor activity was described for patients with
refractory hematological malignancies after adoptive transfer of
haploidentical γδTc (23). Labeling ex vivo expanded haploidenti-
cal γδTc with bispecific antibodies could perhaps further enhance
the cytotoxic capacity of these cells. A further advantage could be
envisioned with respect to the innate lymphocyte capacity of γδTc
to phagocytose and present antigens to αβ T cells, an activity that
may be enhanced in the presence of a bispecific antibody. In the
treatment of solid tumors, the initial administration of n-BP/IL-
2 followed by infusion of bispecific antibody together with IL-2
could probably enhance cytotoxic activity of γδTc, which infiltrate
several different tumor types at low frequency.
CONCLUDING REMARKS
Bispecific antibodies have been designed in different for-
mats. Clinical trials with bispecific antibodies such as Catu-
maxomab (TriomAb [EpCAMxCD3]), Ertumaxomab (Triomab
[HER2xCD3]), and Blinatumomab (Bispecific T Cell Engager
(BiTE) [CD19xCD3]) have delivered impressive therapeutic
results. Additional clinical studies are certainly required to deeper
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evaluate and improve their therapeutic potential. Bispecific anti-
bodies with specificity for CD3 enhance the cytotoxic potential
of αβ as well γδ T cells. However, under certain circumstances, it
would be desirable to activate only γδTc rather than a polyclonal
population of T cells. For instance, CD8+ γδTc were presented
at low frequency but at higher number than CD8+ αβ T cells in
ductal epithelium and nearby stroma in PDAC tissues. This γδTc
accumulation suggests an important role of γδTc in the immune
response against PDAC, which is apparently suppressed by the
pronounced immunosuppressive PDAC-microenvironment.
Together with the monitoring system described in this arti-
cle, the tribody [(Her2)2xVγ9], which selectively targets γδTc and
enhances their cytotoxic activity, provides a tool to determine the
functional capacity of γδTc within the blood or within tumor-
infiltrating T lymphocytes isolated from fresh tumor tissue of
tumor patients. Whether bispecific antibodies targeting γδTc have
the capacity to overcome the immunosuppressive stroma in PDAC
patients, has yet to be investigated in further in vivo studies.
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